GSK3B and breast carcinoma: Report on Toll-like receptor (TLR) agonist-stimulated monocytes showed that after TLR activation, GSK-3β plays a crucial role in controlling pro or anti-inflammatory response [35] and that the inhibition of GSK-3β with LiCl alters NF-κB activity through cross-regulation with β-catenin in colon and breast cancer cells [22].